MultiPepT1De Phase I study

• Research type

  Research Study

• Full title

  Multiple islet peptide administration in Type 1 diabetes (MultiPeT1De)

• IRAS ID

  151224

• Contact name

  Jake Powrie

• Contact email

  jake.powrie@kcl.ac.uk

• Sponsor organisation

  King's College London

• Eudract number

  2014-003830-20

• Duration of Study in the UK

  1 years, 9 months, 1 days

• Research summary

  Type 1 diabetes is an autoimmune disease in which the insulin-secreting β-cells of the pancreas are destroyed such that the patient is reliant on injection of insulin to adequately control blood glucose levels for the remainder of his/her life. The autoimmune process targets proteins in β-cells which are termed autoantigens. This is a Phase 1 study using a novel investigational medicinal product (IMP) known as MultiPepT1De in a study of safety and tolerability of administration in patients with recent-onset Type 1 diabetes. MultiPepT1De is a mixture of peptides from islet autoantigens. The mixture has been designed to induce or restore immunological tolerance to the β-cell and thus control or limit autoimmunity to protect β-cells.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  15/SC/0174

• Date of REC Opinion

  29 Apr 2015

• REC opinion

  Further Information Favourable Opinion